Ra-223 experience in pretreated patients: EAP setting.

201512 citationsJournal Article

Authors

Oliver Sartor

Daniel C. Fernandez · Moffitt Cancer Center

Michael J. Morris · Memorial Sloan Kettering Cancer Center

Andrei Iagaru · Stanford University

Alan S. Brown · 21st Century Oncology (United States)

Fábio Almeida · Imaging Center

Christopher J. Sweeney · Dana-Farber Cancer Institute

Abstract

5063 Background: The early-access program aimed to monitor acute and long-term Ra-223 safety. Herein the number of Ra-223 cycles was examined in relation to prior therapy with abiraterone (abi) and/or enzalutamide (enza). These agents were not approved at the time of the ALSYMPCA trial, the basis for Ra-223 approval. Methods: Symptomatic bone metastatic CRPC patients (pts) and no visceral mets were enrolled in the US if they were ineligible for (or refused) docetaxel (Doc), or had prior Doc. Ra-223 at 50 kBq/kg IV q 4weeks was planned for 6 cycles concomitant with

Topics & Keywords

Radiopharmaceutical Chemistry and Applications Medical Imaging Techniques and Applications Prostate Cancer Treatment and Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 33, Issue 15_suppl, pp. 5063-5063

DOI: 10.1200/jco.2015.33.15_suppl.5063

Field-Weighted Citation Impact: 2.63